Impax Laboratories Inc

Latest Impax Laboratories Inc News and Updates

  • uploads///Graph Part  Dec
    Company & Industry Overviews

    Seattle Genetics and Bristol-Myers Initiate ADCETRIS Trial

    On December 23, 2015, Seattle Genetics and Bristol-Myers Squibb announced the initiation of Phase 1 and 2 clinical trials of ADCETRIS.

    By Peter Neil
  • uploads///solodyn
    Company & Industry Overviews

    Teva’s Recent Launch of Generic Solodyn: What You Need to Know

    On February 20, 2018, Teva Pharmaceutical announced the US launch of the generic version of Solodyn Extended Release tablets in two strengths.

    By Sarah Collins
  • uploads///Cardiovascular
    Company & Industry Overviews

    How Merck’s Cardiovascular Segment Performed in 4Q17 and 2017

    In 4Q17, Merck’s Zetia reported revenues of $323 million, which was ~44% lower on a year-over-year basis and a 1% rise on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///thermometer _
    Company & Industry Overviews

    Depomed versus Peers in March 2018: Analyst Ratings

    Depomed (DEPO) is a specialty pharmaceutical company with a focus on pain and CNS (central nervous system) conditions.

    By Kenneth Smith
  • uploads///Duodopa Revenues
    Company & Industry Overviews

    A Look at AbbVie’s Neuroscience Portfolio

    In 2016, AbbVie’s (ABBV) Duodopa, a combination drug for the treatment of advanced Parkinson’s disease, generated revenue of ~$293 million.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Mylan’s EpiPen Controversy: Is It a Brand or a Generic?

    Mylan has been embroiled in a controversy over whether its EpiPen is classified as a generic or a branded product and whether its 500.0% price hike is justified.

    By Mike Benson
  • uploads///Penetration
    Company & Industry Overviews

    What’s Supporting Continued Growth in the Generics Market?

    The global generics market was valued at $168 billion in 2013. From 2013 to 2018, it’s expected to grow at a CAGR of 11% to reach $283 billion.

    By Nicole Sario
  • uploads///First to files
    Company & Industry Overviews

    Is a Para IV Filing Rewarding for a Generic Company?

    A generic company is rewarded for a Para IV filing. The first applicant to submit a substantially completed ANDA is given marketing exclusivity for 180 days.

    By Nicole Sario
  • uploads///Generics Penetration
    Company & Industry Overviews

    What Two Factors Are Driving the US Generics Market?

    The US generics industry is fragmented. The top five companies accounted for 44.4% of the market share of unbranded generics in 2013, according to IMS Health.

    By Nicole Sario
  • uploads///Classification of Generics
    Company & Industry Overviews

    Why the Generic Industry’s Classification Is Still Evolving

    The generics industry primarily caters to several large diseases in primary care. Healthcare is organized into three categories—primary, secondary, and tertiary.

    By Nicole Sario
  • uploads///Drug Market
    Company & Industry Overviews

    Are Generics the Only Affordable Drugs?

    Drugs are used to treat, cure, or prevent diseases. The drug market is broadly categorized into prescription drugs and OTC (over-the-counter) drugs.

    By Nicole Sario
  • uploads///Prescription Market
    Company & Industry Overviews

    What Investors Need to Know about Branded and Generic Drugs

    The prescription drug market is divided into two categories—branded or generic drugs. Branded drugs are patented drugs. Generics are off-patented drugs.

    By Nicole Sario
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.